Marksans Pharma Share Price (MARKSANS)
as on
| Source : NSE
🔔 Regulatory Approval Alert
Marksans Pharma's subsidiary Relonchem receives UK MHRA marketing authorization for Metformin Hydrochloride Prolonged Release Tablets, enhancing its market presence.
Marksans Pharma Stock Performance
as on August 18, 2025 at 4:01 PM IST
Day's Low
Day's High
₹180₹184.9
2.31%
Downside
0.35%
Upside
52 Week's Low
52 Week's High
₹171₹358.77.19%
Downside
94.68%
Upside
| Market Stats | |
| Previous Close | ₹178.58 |
| Open | ₹180.00 |
| Volume | 15.32L |
| Upper Circuit | ₹214.29 |
| Lower Circuit | ₹142.86 |
| Day's Low | ₹180 |
| Day's High | ₹184.9 |
| 52 Week Low | ₹171 |
| 52 Week High | ₹358.7 |
| Returns % | |
| 1 Month Return | -30.17 % |
| 3 Month Return | -29.56 % |
| 1 Year Return | -18.88 % |
| 3 Year Return | + 244.75 % |
| 5 Year Return | + 243.09 % |
Marksans Pharma Stock Fundamentals & Key Indicators
Check Marksans Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹8,092.60 Cr
Return on Equity (ROE)
14.45
PE Ratio (TTM)
23.1
Return on capital employed (ROCE)
18.55
Industry PE ratio
43.28
Beta (LTM)
1.31
P/B Ratio
7.28
Dividend Yield
0.36
PEG Ratio
64.17
Quarterly Earnings Growth YOY
-34.66
EPS (TTM)
8.44
Sector
Pharmaceuticals
Book Value
54.44
Technical Analysis
Bearish
View Technical Analysis
Marksans Pharma Stock's Interest Amongst Investors
Marksans Pharma Stock Valuation
Track how Marksans Pharma P/E has moved over time to understand its valuation trends.
Marksans Pharma in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (23.10x)
August 14, 2025
Industry (43.28x)
August 14, 2025
Highest (46.60x)
January 24, 2018
Today’s Price to Earnings Ratio: 23.10x
Marksans Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Marksans Pharma.
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
100% of analysts recommend a 'BUY' rating for Marksans Pharma. Average target price of ₹231.67
Source: S&P Global Market Intelligence
Marksans Pharma Share Price Target
Get share price movements and forecasts by analysts on Marksans Pharma.
Marksans Pharma price forecast by 3 analysts
Upside of29.73%
High
₹265
Target
₹231.67
Low
₹210
Marksans Pharma target price ₹231.67, a slight upside of 29.73% compared to current price of ₹184.25. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Marksans Pharma revenue growth forecast
Expected growth rate Q1, FY2027:23.52%
Forecast
Actual
Including amortisation and stock based compensations
Marksans Pharma EPS growth forecast
EPS estimate Q1, FY2027:42.02%
Forecast
Actual
Source: S&P Global Market Intelligence
Marksans Pharma Ltd Financial Results
Get the annual and quarterly financial summary of Marksans Pharma Ltd, including revenue, profit, loss and more.
Marksans Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Marksans Pharma.
Marksans Pharma Ltd Earnings Results
Marksans Pharma Ltd’s net profit fell -34.29% since last year same period to ₹58.32Cr in the Q1 2025-2026. On a quarterly growth basis, Marksans Pharma Ltd has generated -35.59% fall in its net profits since last 3-months.
Read More about Earnings ResultsMarksans Pharma Ltd Dividends May,2025
In the quarter ending March 2025, Marksans Pharma Ltd has declared dividend of ₹0.80 per share on 19 May 2025 - translating a dividend yield of 0.78%.
Read More about Dividends
Indices Featuring Marksans Pharma Stock
Check stock indices that include Marksans Pharma.
Marksans Pharma Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Marksans Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.87% | 0.00 | |
| Foreign Institutions | 11.26% | ||
| Mutual Funds | 3.55% | 5.10 | |
| Retail Investors | 30.75% | 4.71 | |
| Others | 10.57% |
Marksans Pharma Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Marksans Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 8,092.60 | 48.62% | 0.56 | 382 | 2,622 | |
| NA | 697.24 | -1.55% | 0.00 | 30 | 245 | |
| NA | 21.07 | 16.64% | 0.00 | NA | 14 | |
| NA | 2,189.31 | 31.46% | 0.53 | 60 | 759 | |
| NA | 7,764.41 | 8.94% | 0.51 | 305 | 1,942 |
Marksans Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Marksans Pharma.
Marksans Pharma Subsidiary Gains UK Approval for Metformin - 18 Aug, 2025
Marksans Pharma's UK subsidiary, Relonchem, received marketing authorization from the UK MHRA for Metformin Prolonged Release Tablets, enhancing its market presence in diabetes treatment.Marksans Pharma Shares Plummet After Weak Q1 Results - 12 Aug, 2025
Marksans Pharma reported a 34.3% decline in Q1FY26 net profit to Rs 58.3 crore, leading to a 14% drop in share price due to margin pressures.Marksans Pharma Receives USFDA Approval for Drug - 08 Aug, 2025
Marksans Pharma Ltd's subsidiary received USFDA approval for Omeprazole delayed-release tablets, a treatment for heartburn. Shares traded flat despite the news.Marksans Pharma Announces Ex-Dividend Trading Date - 28 Jul, 2025
Marksans Pharma Limited announced that it will trade ex-dividend on August 01, 2025. Additionally, an addendum to the AGM notice was published.
Insights on Marksans Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 3.37% to 3.55% in Jun 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 29.37% to 30.75% in Jun 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 43.87% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 31.3% return, outperforming this stock by 50.2%
NEGATIVE IMPACTPrice Dip
In the last 7 days, MARKSANS stock has moved down by -15.0%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 104.56 Cr → 58.32 Cr (in ₹), with an average decrease of 24.5% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 723.8 Cr → 625.63 Cr (in ₹), with an average decrease of 13.6% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 11.32% to 11.26% in Jun 2025 quarter
About Marksans Pharma Ltd
Revenue: ₹619.99Cr as on June 2025 (Q1 FY26)
Net Profit: ₹58.20Cr as on June 2025 (Q1 FY26)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
| Organisation | Marksans Pharma Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| CEO | Mark Saldanha |
| E-voting on shares | Click here to vote |
Mutual Funds that own Marksans Pharma Stock
Check out the Mutual Funds with significant holdings in Marksans Pharma.
| Funds | Holdings | Prev. 5M |
|---|---|---|
| Kotak Special Opportunities Fund Direct Growth | 2.91% | |
| Bandhan Small Cap Fund Direct Growth | 0.4% | |
| Kotak MNC Fund Direct Growth | 2.03% | |
| UTI Small Cap Fund Direct Growth | 0.83% | |
| UTI Aggressive Hybrid Fund-Growth - Direct | 0.53% |
FAQs
What is Marksans Pharma share price today?
Marksans Pharma share price today stands at ₹184.25, Open: ₹180, Previous Close: ₹178.58, High: ₹184.9, Low: ₹180, 52 Week High: ₹358.7, 52 Week Low: ₹171 as on .
How to buy Marksans Pharma shares ?
To buy Marksans Pharma shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for MARKSANS or Marksans Pharma Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Marksans Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Marksans Pharma?
Today's traded volume of Marksans Pharma is 15.32L. Which means that 15.32L shares of Marksans Pharma were bought and sold on the stock market during today's trading session.
What is Marksans Pharma's market cap today?
Today's market capitalisation of Marksans Pharma is ₹8,092.60 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Marksans Pharma?
Marksans Pharma’s 52 week high is ₹358.7 and 52 week low is ₹171. The current share price of Marksans Pharma is ₹184.25, which is -48.63% down from its 52 week high and 7.75% up from its 52 week low.